

Unaudited Financial Results for the quarter and nine months ended September 30, 2011

Rs. in Lakhs

Sr No	Particulars	3 Months ended		9 Months ended		Previous Period from December 1, 2009 to December 31, 2010
		September 30, 2011	August 31, 2010	September 30, 2011	August 31, 2010	
		Unaudited	Unaudited	Unaudited	Unaudited	
1	Net Sales/ Income from Operations					
	(a) Gross Sales	402,16	249,90	1075,07	676,33	995,98
	Less : Excise Duty	527	1,60	13,10	4,20	6,10
	Net Sales	396,89	248,30	1061,97	672,13	989,88
	(b) Other Operating Income	13,61	6,39	29,21	17,26	29,07
2	Expenditure					
	(a) (Increase)/ Decrease in Stock in Trade & Work in Progress	23,34	(16,12)	12,80	(3,75)	(25,08)
	(b) Consumption of Raw Materials	17,50	13,08	79,00	29,82	44,19
	(c) Purchase of Traded Goods	187,75	160,11	529,72	411,88	628,20
	(d) Employee Cost	47,89	25,43	129,75	71,48	111,20
	(e) Depreciation/ Amortisation	3,79	2,54	10,27	6,80	11,25
	(f) Other Expenditure	70,42	35,44	219,26	101,79	161,93
	(g) Total Expenditure	350,69	220,48	980,80	618,02	931,69
3	Profit from Operations before other Income and Interest (1-2)	59,81	34,21	110,38	71,37	87,26
4	Other Income	488	1,75	13,88	397	6,93
5	Profit Before Interest (3+4)	64,69	35,96	124,26	75,34	94,19
6	Interest	-	-	2	1	4
7	Profit Before Tax	64,69	35,96	124,24	75,33	94,15
8	Tax Expense (including current tax, deferred tax and prior period adjustments for the period)	21,06	12,06	40,73	25,56	33,21
9	Net Profit for the period	43,63	23,90	83,51	49,77	60,94
10	Paid-up Equity Share Capital (Face Value of the share – Rs 10/-)	21,25	13,68	21,25	13,68	13,68
11	Reserves excluding revaluation reserves (as per last audited Balance Sheet)					291,71
12	Basic EPS and Diluted EPS for the periods (not annualised), year to date (not annualised) and for the previous period – Rs.	20.53	17.47	39.30	36.39	44.56
13	Public shareholding					
	Number of Shares	5,315,254	42,47,056	5,315,254	42,47,056	42,47,056
	Percentage of Shareholding	25.01%	31.06%	25.01%	31.06%	31.06%
14	Promoters and promoter group shareholding					
	(a) Pledged/ Encumbered :					
	Number of Shares	-	-	-	-	-
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-
	Percentage of Shares (as a % of the total share capital of the company)	-	-	-	-	-
	(b) Non - encumbered :					
	Number of Shares	15,934,048	94,28,184	15,934,048	94,28,184	94,28,184
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%
	Percentage of Shares (as a % of the total share capital of the company)	74.99%	68.94%	74.99%	68.94%	68.94%

Notes :

1. The results for the quarter and nine months ended September 30, 2011 have been reviewed by the Audit Committee, approved by the Board of Directors and subjected to a "Limited Review" by the auditors of the Company, in compliance with Clause 41 of the Listing Agreement with Bombay Stock Exchange Limited.
2. The Company changed its accounting year from year ended November 30 to year ended December 31 from the previous financial year onwards. Accordingly, the results for the current quarter and nine months are for the period ended September 30, 2011 and the corresponding previous quarter and nine months are for the period ended August 31, 2010.
3. (a) Solvay Pharma India Limited (hereinafter referred to as "Solvay Pharma") has merged with Abbott India Limited (hereinafter referred to as "Company") on August 10, 2011 ('Effective Date') according to the Scheme of Amalgamation ('Scheme') sanctioned by the Hon'ble High Court of Bombay. The swap ratio for the merger is 2:3 i.e. every two shares of Solvay Pharma has entitled their holder to three shares of the Company. The shares have been allotted on September 7, 2011 ('Date of Allotment') and the fractional entitlement of shares (equivalent to 497 shares) was paid in cash with reference to the price prevailing on Date of Allotment.

(b) The amalgamation has been accounted for under the "pooling of interests" method as prescribed by Accounting Standard 14 (AS 14) "Accounting for Amalgamations". Accordingly, the assets, liabilities and reserves of Solvay Pharma as at December 31, 2010 have been taken over at their book values after adjusting for
(i) the financial effect of conflicting accounting policies between the Company and Solvay Pharma
(ii) the additional share capital allotted by the Company (over the share capital of Solvay Pharma) and cash paid for the fractional shares.

(c) Under the Scheme, the amalgamation has taken place with effect from January 1, 2011 ('The Appointed Date'). Accordingly the above results for the quarter and nine months ended September 30, 2011 include the results of Solvay Pharma. The results for the previous quarter and nine months ended August 31, 2010 and for 13 months ended December 31, 2010 are for Abbott India Limited before merger with Solvay Pharma.

(d) As on September 30, 2011, certain assets, liabilities and arrangements of Solvay Pharma are in the process of getting transferred to the Company.
4. In view of the change of accounting year referred to in note 2 above and the amalgamation referred to in note 3 above, the results for the quarter and nine months ended September 30, 2011 are not comparable to those of the corresponding previous periods.
5. The Company continues to make strategic investments for expanding its field force and improve market coverage. The Company also continues to increase advertisement & promotional efforts to capture market share and increase brand equity & patient/ customer awareness. These initiatives are impacting the near term profitability. Further, the other expenses for the nine months ended September 30, 2011 also includes integration & amalgamation expenses and stamp duty.
6. The Company (including Solvay Pharma) operates in one reportable business segment i.e. "Pharmaceuticals" and one reportable geographical segment i.e. "Within India".
7. There was 1 investor complaint pending at the beginning of the quarter. The Company received 9 complaints from the investors. All complaints have been resolved and disposed off during the quarter. There was no complaint lying unresolved at the end of the quarter.
8. Figures for the prior period have been regrouped and/or reclassified wherever considered necessary.

Abbott India Limited

Vivek Mohan
Managing Director

Mumbai
November 1, 2011